Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Duo Lu

Showing results (61-70 of 61) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 61 results.
The Lancet. Oncology|November 29, 2024
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trialXiu-Chun Chen, De-Chuang Jiao, Jiang-Hua Qiao, et al.
Pageof 7

Showing results (61-70 of 61) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 61 results.
The Lancet. Oncology|November 29, 2024
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trialXiu-Chun Chen, De-Chuang Jiao, Jiang-Hua Qiao, et al.
Pageof 7